secwatch.observer — SEC 8-K summary
======================================

Issuer:     Turn Therapeutics Inc. (TTRX)
CIK:        0002023016
Form:       8-K
Filed at:   2025-11-13T23:59:59+00:00
Accession:  0001213900-25-109580
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Turn Therapeutics Q3 net loss $1.9M; enters global Medline PermaFusion deal
---------------------------------------------------------------------------

- Net loss of $1.9M ($0.07/share) vs $0.67M loss in Q3 2024; G&A surged to $1.75M on listing costs.
- Cash and equivalents $3.11M at Sept 30, 2025, up from $0.87M at Dec 31, 2024.
- Closed global supply/development/license agreement with Medline for PermaFusion platform.
- Started trading on Nasdaq under TTRX on Oct 8, 2025; appointed two new board members.
- Commenced clinical trial of topical IL-36/IL-31 inhibitor for eczema.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2023016/000121390025109580/0001213900-25-109580-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2023016/000121390025109580/ea0265413-8k_turn.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-109580

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer